Ashley M. Eckel

Dr. Ashley M. Eckel

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in Blood Cancer Discovery
Verified
Journal Article
Closed access
CLCurtis Lachowiez
Curtis Lachowiez
MHMael Heiblig
Mael Heiblig
GRGaspar Aspas Requena
Gaspar Aspas Requena
ETEmmanuelle Tavernier-Tardy
Emmanuelle Tavernier-Tardy
FDFangyan Dai
Fangyan Dai
DPDaniel A. Pollyea
Daniel A. Pollyea
Resistance to venetoclax (VEN)-based therapy in acute myeloid leukemia (AML) includes genetic (i.e., mutations in N/KRAS, FLT3-ITD, TP53) and phenotypic (i.e., monocytic differentiation) features. Whether monocytic differentiation contributes to clinical VEN resistance secondary to a genetic bias remains unknown. This multimodal, multicenter, international analysis, inclusive of 678 patients, comprehensively characterized the prognostic role of monocytic differentiation in patients with AML treated with hypomethylating agents combined with VEN. AML genetics and monocytic differentiation (HR = 1.89; 95% confidence interval, 1.35–2.66; P < 0.001) in NPM1 wild-type cases correlated with an increased risk of death, clustering of centralized quantitative multiparameter flow cytometry data, evaluation of RNA sequencing-derived AML maturation stage, and single-cell proteogenomics linked driver mutations with AML phenotype and antiapoptotic gene expression. This comprehensive analysis of AML genetics, phenotype, and antiapoptotic protein expression highlights the complementary role these factors impart following VEN-based therapy. Significance: AML with monocytic differentiation often occurs in the context of co-occurring mutations within signaling pathways. In certain AML subgroups (such as NPM1 wild-type and signaling pathway gene–mutated), a monocytic phenotype is associated with decreased overall survival following VEN-based therapy. See related commentary by Renders, p. 403

17 October 2019 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
PDF file
AEAshley M. Eckel
Ashley M. Eckel
SCSindhu Cherian
Sindhu Cherian
VMValerie Miller
Valerie Miller
LSLorinda Soma
Lorinda Soma
Detection of minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) is important for guiding patient‐specific clinical management. Natural killer (NK) cells can express various markers not typically associated with NK lineage, potentially confounding the detection of MRD by flow cytometry. We have observed CD33 expression on NK cells when evaluating for AML MRD in routine clinical practice in multiple patient samples. To characterize CD33 expression on NK cells, 40 peripheral blood or bone marrow samples with NK cells present at >5% of lymphocytes were selected for further assessment of NK cell phenotype and CD33 expression. Seven of the 40 samples (17.5%) were found to have CD33 expression on at least 5% of the NK cells. The CD33‐positive NK cell population accounted for an average of 11.4% of NK cells (median 11.9%, range 8.0–15.3%) and 2.2% of total white cells (median 1.1%, range 0.1‐10.1%). This NK cell subset expressed bright CD2, bright CD56, and dim CD16. On average, CD33 expression on NK cells was dimmer than on monocytes (mean median fluorescence intensity ratio 0.4; range 0.1‐1.0). This study characterizes expression of CD33 on NK cells. Recognition of this pattern of antigen expression is critical in evaluating samples for MRD in patients with myeloid neoplasms, particularly AML.

1 August 2024 in Blood
Verified
Journal Article
Closed access
PDF file
JCJacqueline A. Cook
Jacqueline A. Cook
LLLoren Lott
Loren Lott
JPJenna Perry
Jenna Perry
AEAshley M. Eckel
Ashley M. Eckel
DXDongbin Xu
Dongbin Xu
AMAndrew J. Menssen
Andrew J. Menssen
Molecular measurable residual disease can persist in core-binding factor acute myeloid leukemia in otherwise disease-free patients. Utilizing cell sorting followed by fluorescent in situ hybridization, we show that detection is due to mast cells.

1 January 2017 in Journal of Clinical and Experimental Dentistry
Verified
Journal Article
Open access
AEAshley M. Eckel
Ashley M. Eckel
DLD Lee
D Lee
GDG Deutsch
G Deutsch
AMA Maxin
A Maxin
DOD Oda
D Oda
Crohn?s disease (CD) is a chronic inflammatory disorder affecting the gastrointestinal (GI) tract. Although the GI tract is the primary site of involvement, many patients, particularly in pediatric cases, first present with non-intestinal manifestations, including oral lesions. Oral manifestations of CD in children occur in around 50-80% of cases, and about 30% of CD cases in children occur first in the mouth. Recognizing such oral lesions in the pediatric population, and requesting a biopsy, may expedite the diagnosis of CD. We describe a 15 year old male who presented with oral findings of multiple aphthous ulcers and plaques of pink papules of the buccal vestibule. We highlight the initial pathology findings, including non-caseating granulomas, sialadenitis, and a notable plasmacytosis, from biopsy of the left retromolar pad area, which triggered further testing for CD. We provide discussion of how CD was eventually diagnosed and treated and highlight the significance of the pathological findings in this case as they relate to the pathogenesis of CD

1 August 2017 in Southern Medical Journal
Verified
Journal Article
Closed access
AEAshley M. Eckel
Ashley M. Eckel
JHJohn R. Hess
John R. Hess
MDMd
Md
PDPh D
Ph D
Recognition of the acute coagulopathy of trauma and the limits of reconstituting whole blood with conventional blood components has led to a radical change in the way trauma patients with severe injuries are resuscitated. Massive transfusion protocols (MTP) have evolved toward the administration of conventional blood components in fixed ratios. Administration of a 1:1:1 unit ratio of fresh frozen...

16 March 2024 in Cancer Genetics
Verified
Journal Article
Closed access
CHChia-Chen Ho
Chia-Chen Ho
KNKikkeri Naresh
Kikkeri Naresh
YLYajuan Liu
Yajuan Liu
YWYu Wu
Yu Wu
AGAjay K Gopal
Ajay K Gopal
AEAshley M. Eckel
Ashley M. Eckel